Skip to main content

Table 1 Baseline clinical characteristics

From: Impact of hyperuricemia on clinical outcomes after percutaneous coronary intervention for in-stent restenosis

 

Normal UA

(n = 251)

Higher UA

(n = 66)

p-value

Age (year)

64.6 ± 9.9

65.3 ± 10.3

0.609

Men, n (%)

182 (72.5)

57 (86.4)

0.030

Body mass index

24.8 ± 3.0

25.6 ± 2.9

0.056

Current smoker, n (%)

61 (24.3)

16 (24.2)

1.000

Hypertension, n (%)

175 (69.7)

53 (80.3)

0.122

Diabetes, n (%)

91 (36.3)

25 (37.9)

0.920

Prior MI, n (%)

69 (27.5)

23 (34.8)

0.308

Diagnosis at the index PCI

SA/UA, n (%)

NSTEMI/STEMI, n (%)

210 (83.7)

41 (16.3)

54 (81.8)

12 (18.2)

0.863

Laboratory findings

Uric acid (mg/dL)

4.9 ± 1.1

7.4 ± 1.6

<.001

Total cholesterol (mg/dL)

150.1 ± 37.3

148.8 ± 43.8

0.817

LDL-C (mg/dL)

85.9 ± 29.5

90.6 ± 36.4

0.345

HDL-C (mg/dL)

43.6 ± 11.0

42.0 ± 12.7

0.333

Triglyceride (mg/dL)

127.5 ± 75.6

147.2 ± 78.1

0.064

Glucose (mg/dL)

122.5 ± 42.0

121.8 ± 42.9

0.900

Creatinine Clearance (mL/min)

72.3 ± 22.5

63.3 ± 26.2

0.006

hsCRP (mg/L)

4.3 ± 10.6

5.8 ± 12.9

0.407

LVEF (%)

56.2 ± 7.9

53.5 ± 11.4

0.095

Medications

DAPT

248 (98.8)

64 (97.0)

0.610

Anti-hyperuricemic agent

–

18 (27.3)

–

  1. Data were presented as n (%) or mean ± SD. DES, drug-eluting stent; DCB, drug-coated balloon; MI, myocardial infarction; PCI, percutaneous coronary intervention; SA, stable angina; UA, unstable angina; NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; hsCRP, high sensitivity C-reactive protein; LVEF, left ventricular ejection fraction; DAPT, dual anti-platelet treatment